ErlySign Raises Rs 16 Crore to Transform Cancer Detection: This Simple Saliva Test Could Save Millions of Lives!
What if we told you that detecting oral cancer could be as simple as spitting in a tube? No painful biopsies. No long wait for results. Just a 15-minute saliva test that could catch cancer before it spreads. Sounds like science fiction? Well, it’s real—and ErlySign is making it happen.
With a Rs 16 crore investment led by the legendary Ashish Kacholia, ErlySign, formerly known as CURO Biosciences, is poised to revolutionize the world of cancer diagnostics. This breakthrough technology could make early cancer detection faster, cheaper, and less invasive than ever before.
How Does ErlySign’s Saliva Test Work?
Let’s face it—cancer detection has always been invasive and expensive. But ErlySign is about to change all that. Their salivary biomarker-based kit can detect oral precancerous conditions in just 15 minutes by simply analyzing your saliva.
The magic? Specific biomarkers in your saliva that can tell doctors whether you’re at risk of oral cancer—without the need for painful and expensive procedures like biopsies.
With 100% specificity and 98.04% sensitivity, this test is incredibly accurate. It’s already in final clinical trials at multiple HCG (Healthcare Global Enterprises) sites, and it has already earned patents in India and the U.S.. The test is now one step away from approval by the CDSCO (Central Drugs Standard Control Organisation) in India, paving the way for a mass-market release.
Why Is This Saliva Test a Game Changer?
Imagine this: You walk into a clinic, give a saliva sample, and get your cancer results in just 15 minutes. No needles. No waiting days for results. This simple, fast, and non-invasive test could revolutionize how we think about cancer detection.
Why This Test Is a Life-Saver:
- Speed: Results in just 15 minutes. No more waiting for days.
- Non-Invasive: Say goodbye to painful procedures—just spit into a tube!
- Highly Accurate: 98.04% sensitivity means fewer false negatives and more peace of mind.
- Affordable: The test will be cost-effective, making cancer detection accessible to millions.
A Growing Need for Affordable Cancer Tests
Oral cancer is one of the top 3 cancers in India, and with rising tobacco use and poor oral hygiene, the need for early, affordable detection has never been more urgent. The global diagnostics market is projected to hit $250 billion by 2030, and India is a massive market for innovative, low-cost cancer solutions.
ErlySign’s breakthrough test is set to reduce unnecessary biopsies, ease the burden on patients, and help doctors catch cancer early, when treatment is most effective. This isn’t just a win for healthcare—it’s a game changer for millions of people worldwide.
The Future Is Bright: ErlySign Plans to Detect More Than Just Oral Cancer
Here’s where it gets even more exciting: ErlySign’s innovation isn’t limited to oral cancer. The company is working on using CRISPR miRNA-based technology to detect multiple types of cancer—all from the same saliva sample.
What does that mean? You could soon be able to detect breast cancer, lung cancer, cervical cancer, and oral cancer—all in 15 to 20 minutes. One test, multiple cancers. It’s a game-changer that could save countless lives and transform cancer care forever.
Where Will the Rs 16 Crore Go?
With this fresh investment of Rs 16 crore, ErlySign is gearing up for big things:
1. Speeding Up Research and Development:
The team will continue to improve the technology and develop additional cancer tests. They’re not stopping at oral cancer—they’re aiming for a multi-cancer detection platform that will detect several cancers with just one sample.
2. Expanding the Team:
ErlySign plans to bring in more experts to accelerate the product development, expand their operations, and make this breakthrough available to a global audience.
3. Going Global:
ErlySign aims to file more patents across the world, expanding their reach and ensuring that their innovative technology can help millions of people worldwide.
The Backing of Big Names
ErlySign’s journey has been supported by some of the brightest minds in the field, including Dr. Vishal Rao, a renowned oncologist. Rao has been a key mentor, offering his clinical expertise to help shape ErlySign’s technology and ensure it meets the highest standards.
“ErlySign’s saliva test has the potential to transform cancer diagnostics, especially in areas where access to healthcare is limited,” says Dr. Vishal Rao. “This could save lives by detecting cancer in its earliest, most treatable stages.”
Why This Matters: A More Accessible, Affordable, and Faster Way to Detect Cancer
Cancer is one of India’s biggest health threats, and the need for early detection has never been more pressing. Traditional methods are often expensive, invasive, and hard to access, but ErlySign’s innovative saliva test could make early cancer detection much easier and accessible.
With India’s healthcare infrastructure already under pressure, solutions like ErlySign’s test could be the key to improving survival rates, reducing healthcare costs, and giving people the ability to detect cancer early, when it’s most treatable.
The Road Ahead: A Healthier, Safer Future with ErlySign
With this Rs 16 crore investment, ErlySign is ready to scale its operations and take its life-saving technology to the next level. The future of cancer detection is fast, simple, and non-invasive—and ErlySign is at the forefront of this revolution.
Imagine a world where cancer detection is as easy as spitting into a tube. That world is closer than you think—and ErlySign is making it happen.
Conclusion: Why You Need to Keep an Eye on ErlySign
ErlySign’s saliva-based cancer test is a game changer. By making cancer detection faster, cheaper, and less invasive, ErlySign is setting the stage for a new era in healthcare. With the help of Ashish Kacholia, Dr. Vishal Rao, and their growing team, this innovation has the potential to save millions of lives.
The future of cancer detection is here—and it’s simple, quick, and life-saving.
